Qaelon is pioneering the first and only platform that combines real-time detection of life-threatening surgical leaks and state of the art surgical insufflation.

Trusted executive consultant providing outsourced senior leadership for early-stage medical device startups, product development, and product launches. Clients include Ethicon, KCI, J&J Dermatology, Novartis Diabetes, Modular Medical, Dextera, Z-Medica, Omni-stat Medical, and Cornell University. Select engagements include: ~GENERAL MANAGER, MyAir, Inc. (2021 – 2022). Developed comprehensive US business strategy for hospital grade respiratory monitoring device and consumer wearable platform in treatment of COPD and CHF. ^ Developed strategies for commercialization, fundraising, reimbursement, and regulatory approval. ^ Led business development, strategic partnership implementation, and investor deck development. ^ Authored FDA regulatory submission and Emergency Use Authorization for patients with COVID. ~CHIEF COMMERCIAL OFFICER (Acting) and Board Member, Modular Medical, Inc. (2019 – 2020). Provided commercial leadership and executive coaching to CEO of next generation disposable insulin pump. ^ Developed commercialization strategy, market model, branding, packaging, and pricing. ^ Drove product refinement and feature prioritization aligning marketing strategy, competitive market analysis, and user-based primary market research.~CHIEF EXECUTIVE OFFICER/CHIEF COMMERCIAL OFFICER, Endo-TAGGS, Inc. (2018 – 2019). CEO/CCO of pre-commercial first and only gastric access trocar for endoscopic treatment of GERD, Obesity, and GI cancer. ^ Created business plan, investor presentation, commercialization strategy, and market model. ^ Reduced COGS by 70% through product design refinements. ^ Expanded IP with two new products increasing total available market (TAM) from $71M to $230M. ^ Developed clinical strategy and pre-clinical labs resulting in two Harvard Medical School publications. ^ Co-authored U.S. regulatory strategy and led pre-submission meeting with FDA.

Drove double-digit revenue growth for Conmed’s largest division ($500M annual revenue). Shared responsibility for corporate revenue, income, and EPS goals. P&L responsibility for commercial team spanning four medical device portfolios in minimally invasive, robotic, and open surgery. Led remote team of 30 and $12M budget. ^ Accelerated double-digit revenue growth for Conmed with launch of AirSeal Robotic Solution – fastest new product in company history to achieve $10M revenue with 60K procedures (11 months). ^ Increased profit $13M and improved margins over two years with revamped pricing strategy. ^ Refined new product design process increasing speed to market and reducing R&D costs. Saved $600K and 6 months in pre-clinical trials for largest innovation in pipeline. ^ Dramatically improved team’s Gallup Engagement Score in first year from 29th to 74th percentile. ^ Developed Conmed’s first ever integrated digital marketing campaign, delivering 35% procedure growth. ^ Collaboration expanded the role of marketing from sales support to fully integrated commercial team. ^ Leveraged personal KOL network to increase sales, optimize product portfolio, and accelerate pipeline. ^ Implemented several company-wide process improvements to build foundation for sustainable growth

Selected by private equity owners (Savitr Capital) to turnaround pre-commercial biosurgery company developing fistula repair products. Responsible for P&L, finance, product development, manufacturing, R&D, regulatory, clinical trials, and Chief Commercial Officer. Quickly assessed clinical performance and IP to pivot strategy from medical device to drug delivery. Reported to Board of Directors, managed 30 FTE and $20M operating expense. ^ Reduced cash burn 30% to extend life of the company 6 months through pipeline prioritization, operations consolidation, team restructuring, and cost-cutting. ^ Reduced cost-of-goods 35% through product refinements and contract negotiation with leading CMO. ^ Revamped failing quality management system, documented procedures, and completed transition of CE mark to BSI Notified Body and latest ISO 13485:2016 with zero inspection observations. ^ Developed network of KOL’s to review R&D pipeline and stem cell drug delivery combination therapy. ^ Positioned company’s IP assets for sale when lead product had mixed clinical results.

Selected by investment bankers (Wedbush) to lead commercial team and pivot company from cardiac to minimally invasive surgery for industry’s first 5mm surgical stapler. Led company from product concept to acquisition for 6X revenue. Co-led fundraising and investor management with CEO. Managed global team of 40 across 8 countries. ^ Co-led fundraising of $53M exceeding goal by $15M. ^ Created new market model, commercialization strategy, and executed global launch. ^ Provided clinical support to European FDA trial investigators that led to FDA clearance. ^ Developed pricing strategy and negotiated GPO contracts achieving 80% coverage of U.S. market, 20% of Germany, and listing on 100% of UK hospitals despite entrenched competitors (J&J and Medtronic). ^ Recruited global network of 150+ world renowned KOLs, achieving podium presence at every major surgical society meeting after product launch. ^ Co-wrote clinical trial protocol and led recruitment of surgeons for study that expanded product claims. ^ Built and trained global network of distributors in 8 countries, including strategic partnership with conglomerate B Braun Aesculap (Spain) that led to company acquisition.

Chief Operating Officer & Co-founder Created first ever metabolic health summit for medical, surgical, industry, and health policy leaders, resulting in expanded CMS reimbursement of bariatric surgery for type 2 diabetes and updated ADA treatment guidelines. ^ Raised $1M in sponsorships from medical device, pharmaceutical, and consumer companies. ^ Attracted faculty including Ministers of Health of UK, Mexico, and medical society executives. ^ Endorsed by 26 professional societies with 1,000+ attendees from 43 countries.

Led marketing and product development for pre-IPO start-up of first computer powered surgical stapler. Supported IPO process with creation of S-1, investor materials, and comprehensive market model. Reversed declining sales with 3 new product launches, increasing revenue 21% and leading to acquisition by Medtronic.

Award-winning sales and marketing leader with proven track record of profitable growth. P&L responsibility for Biosurgery Division (internal start up) driving driving top line revenue from $68M to $190M over 5 years (23% CAGR) while growing bottom-line profit 3X faster than expenses. Led 8 best-in-class global product launches. Scaled sales force from 19 to 70 reps. Ranked #1 sales manager (out of 9) and #1 sales representative (out of 250).